Biogen and Eli Lilly Announce Major Acquisitions; Healthcare Industry Sees Consolidation Wave
Today marks a significant shift in both the pharmaceutical landscape and healthcare access dynamics.
Two major acquisitions totaling $11.9B - Biogen's purchase of Apellis and Eli Lilly's acquisition of Centessa - signal aggressive expansion in immunology and r…
Two major acquisitions totaling $11.9B - Biogen's purchase of Apellis and Eli Lilly's acquisition of Centessa - signal aggressive expansion in immunology and rare disease treatments. Meanwhile, the intersection of policy and healthcare economics is creating new pressure points, with states investing millions in Medicaid verification systems while seeing minimal fraud, and a marked increase in self-pay patients due to ACA credit expiration and rising costs. The healthcare lab…
One pattern. Trace it.
- 01
A pattern worth naming
Watch for: 1) Post-merger integration announcements from Biogen and Eli Lilly within 60 days, particularly regarding product pricing and distribution strategies; 2) State-by-state Medicaid verification cost reports through Q2 2026; 3) Healthcare provider bad debt trends in Q2 2026 as self-pay increases; 4) Additional biotech workforce reductions in major hub cities within 90 days.
Ask your CFO whether the unit economics on every new service line still pencil under the new rate environment.
By Joseph Lancaster, Editor — with research from Pine Needle's intelligence layer.
The next argument lands tomorrow at 6 a.m. Pacific. Get it in your inbox →